A Multi-Center, Randomized, Double Masked, Placebo Controlled Clinical Study to Assess the Safety and Efficacy of RGN-259 Ophthalmic Solutions for the Treatment of Dry Eye: ARISE-1

Trial Profile

A Multi-Center, Randomized, Double Masked, Placebo Controlled Clinical Study to Assess the Safety and Efficacy of RGN-259 Ophthalmic Solutions for the Treatment of Dry Eye: ARISE-1

Completed
Phase of Trial: Phase II/III

Latest Information Update: 09 May 2017

At a glance

  • Drugs Thymosin-beta-4 (Primary)
  • Indications Dry eyes
  • Focus Therapeutic Use
  • Acronyms ARISE-1
  • Sponsors ReGenTree
  • Most Recent Events

    • 09 May 2017 Results from this trial will be presented at the 2017 ARVO meeting, according to a RegeneRX Biopharmaceuticals media release.
    • 17 Aug 2016 Status changed from active, no longer recruiting to completed.
    • 06 May 2016 According to a RegeneRX Biopharmaceuticals media release, the company intends to meet the US FDA in June in order to provide full results of this study.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top